Form 4: Sutro Biopharma Executive Jane Chung Reports Stock Transactions

Sutro Biopharma's President and COO, Jane Chung, reports the acquisition of 25,000 shares through vesting of restricted stock units and the withholding of 8,920 shares for tax obligations.

Summary

• Jane Chung, President and COO of Sutro Biopharma, reported transactions involving the company's stock on December 1, 2024.
• She acquired 25,000 shares of common stock through the vesting of restricted stock units (RSUs).
• Additionally, 8,920 shares were withheld by the company to cover income tax obligations related to the RSU vesting.
• Following these transactions, Ms. Chung directly owns 70,342 shares of Sutro Biopharma common stock.
• She also holds 75,000 restricted stock units that vest over the next three years.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative events. The vesting of RSUs is a positive sign of continued service and performance.

Positives

• The vesting of RSUs indicates that Ms. Chung is meeting her performance targets and remaining with the company.
• The acquisition of shares through vesting increases her stake in the company, aligning her interests with shareholders.

Negatives

• The withholding of 8,920 shares for tax obligations reduces the net gain from the RSU vesting.

Risks

• The value of the shares is subject to market fluctuations, which could impact the overall value of Ms. Chung's holdings.
• Future vesting of RSUs is contingent on continued service with the company.

Future Outlook

The remaining 75,000 RSUs will vest annually over the next three years, subject to continued service.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It provides transparency into the stock ownership of key personnel.

Comparison to Industry Standards

• The vesting of restricted stock units is a common practice for executive compensation in the biotechnology industry.
• The tax withholding of shares is a standard procedure to cover income tax obligations related to equity compensation.
• Other biotechnology companies such as Amgen and Gilead Sciences also use similar equity compensation plans for their executives.

Stakeholder Impact

• The transactions increase the alignment of interests between the executive and shareholders.
• The vesting of RSUs is a positive sign for employees as it indicates the company is meeting its compensation obligations.

Key Dates

Keywords

Sutro Biopharma, Jane Chung, insider trading, Form 4, restricted stock units, RSU, stock ownership, executive compensation